Notes

Formate Dehydrogenases Lessen CO2 Instead of HCO3- : An Electrochemical Demonstration.
ding to ineffective transfusion. Copyright © 2020, Spandidos Publications.Role of long-chain non-coding ribonucleic acid (lncRNA) GACAT1 in the development of breast cancer and its possible mechanism were investigated. The levels of GACAT1, microRNA-875-3p and Stonin2 (STON2) in breast cancer tissues and adjacent normal tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). The level of GACAT1 in breast cancer cell lines was further explored. The effects of GACAT1 and microRNA-875-3p on cell proliferation and cycle were detected by cell counting kit-8 (CCK-8) and flow cytometry. The binding relationship between microRNA-875-3p and STON2, microRNA-875-3p and GACAT1 was examined by a dual luciferase reporting assay. It was confirmed by rescue experiments whether GACAT1 canregulate the level of STON2 by binding to microRNA-875-3p. GACAT1 level was clearly enhanced in breast cancer tissues compared to that of the adjacent tissues. Similar result was observed in breast cancer cell lines. Upregulation of GACAT1 promoted the proliferation and cycle of breast cancer cells including MCF-7 and BCap-37. The dual luciferase reporting assay results indicated that GACAT1 had a binding relationship with microRNA-875-3p. Further experiments confirmed that microRNA-875-3p was conspicuously downregulated in breast cancer tissues, and upregulation of microRNA-875-3p could inhibit the proliferation ability of MCF-7 and BCap-37 cells, and partially reversed the promoting effect of GACAT1 on cell cycle. Through bioinformatics prediction and dual luciferase reporter gene experiments, we found that STON2 might be a target gene of microRNA-875-3p. Overexpression of STON2 could partially abolish the effect of microRNA-875-3p on cell proliferation and cycle of MCF-7 and BCap-37 cells. SH-4-54 clinical trial GACAT1 can participate in the progression of breast cancer by promoting the proliferation and cycle of breast cancer cells. The mechanism may be through the regulation of the level of STON2 by adsorbing microRNA-875-3p. Copyright © Wang et al.Efficacy of trastuzumab, carboplatin and docetaxel in human epidermal growth factor receptor-2 (HER-2)-positive breast cancer patients was investigated. A total of 180 HER-2-positive breast cancer patients admitted to The First People's Hospital of Yunnan Province were selected, of which 80 patients were treated with carboplatin and docetaxel and served as the control group (CG), and 100 patients were treated with trastuzumab, carboplatin and docetaxel and served as the research group (RG). Clinical efficacy, pathological efficacy, adverse reactions, inflammatory factors interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), cellular immune indexes of T-lymphocyte subsets (CD4+, CD8+, CD4+/CD8+), and the oxidative stress indexes superoxide dismutase (SOD) and myeloperoxidase (MPO) were observed before and after treatment and were compared between both groups. Patients were followed up for 5 years, and the 5-year disease-free survival (DFS), as well as the overall survival (OS) were compared. Clinical efficacy and pathological efficacy in the RG were significantly higher than those in the CG, and the incidence rate of adverse reactions had no significant difference between the two groups. There was no significant difference in inflammatory factors, cellular immune indexes and oxidative stress indexes between the two groups before treatment. After treatment, the levels of IL-6, TNF-α, CD8+ and MPO in both groups were significantly reduced and were significantly lower in RG than those in CG. However, the levels of CD4+, CD4+/CD8+ and SOD in both groups were significantly increased after treatment and were significantly higher in RG than those in CG. The 5-year DFS and OS of the RG were significantly higher than those of the CG. In conclusion, trastuzumab, carboplatin and docetaxel present high efficacy, safety, and 5-year DFS and OS in HER-2-positive breast cancer patients, and have good recovery effect on inflammation, immune response and oxidative stress. Copyright © 2020, Spandidos Publications.Effect of nalbuphine on patient-controlled intravenous analgesia (PCIA) after radical resection of colon cancer was explored. Retrospective analyses of 100 patients who underwent elective laparoscopic radical resection of colon cancer in Xiang Yang No. 1 People's Hospital, Hubei University of Medicine from June 2014 to December 2016 were made. Forty-seven patients were treated with nalbuphine as experimental group and 53 cases were treated with morphine as control group. All patients received PCIA after surgery. According to visual analogue scale (VAS), pain degree at 2, 4, 8, 12 and 24 h after surgery, total dosage of analgesia pump, total times and effective times of pressing were evaluated. Analgesic satisfaction rate, and adverse reactions such as nausea, vomiting, dizziness and headache at the same time were observed and recorded. The postoperative VAS in the experimental group was evidently lower than that in the control group (P0.05). After laparoscopic radical resection of colon cancer, nalbuphine is effective in PCIA, with low incidence of adverse reactions and high safety. Copyright © 2020, Spandidos Publications.Changes of serum miR-223-3p in patients with oral cancer treated with TPF regimen and the prognosis were investigated. Fifty patients with oral cancer treated in the Affiliated Stomatological Hospital of Jiamusi University from March 2014 to January 2016 were enrolled in the study group, while 50 healthy subjects receiving physical examinations during the same period were enrolled in the control group. Serum expression of miR-223-3p was quantified by RT-qPCR. The diagnostic value of miR-223-3p in oral cancer was analyzed by the receiver operating characteristic (ROC) curve. Expression of miR-223-3p before and after treatment was compared. The study group was divided into the remission and the non-remission group based on the treatment outcome to analyze the predictive value of miR-223-3p. Patients were followed up for 3 years. Cox regression analysis was performed to analyze the independent prognostic factors. The relative serum miR-223-3p level was lower in the study than in the control group (P less then 0.
Here's my website: https://www.selleckchem.com/products/sh-4-54.html